bcl-2 expression in the spectrum of preinvasive breast lesions

Cancer

Volumn 77, Issue 3, 1996, Pages 499-506

  Siziopikou, Kalliopi P ^a,b   Prioleau, John E ^a   Harris M, Jay R ^a   Schnitt, Stuart J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

atypical hyperplasia; bcl 2; breast; ductal carcinoma in situ; hyperplasia; lobular neoplasia; p53

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ARTICLE; BREAST BIOPSY; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST HYPERPLASIA; CANCER GRADING; CARCINOMA IN SITU; CELL DEATH; CLINICAL FEATURE; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

EID: 0030039556     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19960201)77:3<499::aid-cncr11>3.0.co;2-%23     Document Type: Article

References (43)

1. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961-5.
2. Baer R. Bcl-2 breathes life into embryogenesis. Am J Pathol 1994;145:7-10.
3. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.
4. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
5. Stewart BW. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 1994;86:1286-96.
6. Inghirami G, Frizzera G. Role of the Bcl-2 oncogene in Hodgkin's disease. Am J Clin Pathol 1994;101:681-3.
7. van den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994;145:294-300.
8. Pilotti S, Collini P, Rilke F, Cattoretti G, Del Bo R, Pierotti MA. BCL-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994;172:337-42.
9. Segal NH, Cohen RJ, Haffejee Z, Savage N. BCL-2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 1994;118:616-8.
10. Bronner MP, Culin C, Reed JC, Furth EE. The bcl-2 protooncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 1995;146:20-6.
11. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-9.
12. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
13. Joensuu H, Pylkkänen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145:1191-8.
14. Bhargava V, Kell DL, van de Rijn M, Warnke RA. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994;145:535-40.
15. Doglioni C, Dei Tos AP, Laurino L, Barbareschi M, Chiarelli C, Viale G. bcl-2 expression in breast carcinoma. Mod Pathol 1994;7:15A.
16. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-1805.
17. Lotem J, Sachs L. Regulation by bcl-2, c-myc and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 1993;4:41-7.
18. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55:2698-2708.
19. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 1992;23:1095-7.
20. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-80.
21. Farber E. Programmed cell death: necrosis versus apoptosis. Mod Pathol 1994;7:605-9.
22. Poller DN, Roberts EC, Bell JA, Elston CW, Blarney RW, Ellis IO. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 1993;24:463-8.
23. Dosaka-Akita H, Shindoh M, Fujino M, Kinoshita I, Akie K, Katoh M, et al. Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am J Clin Pathol 1994;102:660-4.
24. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
25. Hockenbery D, Oltvai Z, Yin X-M, Milliman C, Korsmeyer SJ. bcl-2 functions in an antioxidant pathway of apoptosis. Cell 1993;75:241-51.
26. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991;67:879-88.
27. Strasser A, Harris AW, Cory S. bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 1991;67:889-99.
28. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
29. Ginsberg D, Mechta F, Yaniv M, Oten M. Wild-type p53 can down modulate the activity of various promoters. Proc Natl Acad Sci USA 1991;88:9979-83.
30. Mercer WE, Shields MT, Lin D, Appella E, Ullrich SJ. Growth suppression induced by wild-type p53 is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci USA 1991;88:1958-62.
31. Wang Y, Szekely L, Okan J, Klein G, Wiman G, Wiman KL. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 1993; 8:3427-31.
32. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-7.
33. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994;145:1323-36.
34. Eriksson ET, Schimmelpenning H, Aspenblad U, Zetterberg A, Auer GU. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. Hum Pathol 1994;25:1228-33.
35. Humphrey PA, Franquemont DW, Geary WA, Kerns BM, Iglehart JD, Marks JR. Immunodetection of p53 protein in noninvasive epithelial proliferative breast disease. Appl Immunohistochem 1994;2:22-8.
36. Younes M, Lebovitz RM, Bommer KE, et al. p53 accumulation in benign breast biopsy specimens. Hum Pathol 1995;26:155-8.
37. Battifora H. p53 immunohistochemistry: a word of caution. Hum Pathol 1994;25:435-7.
38. Lohmann D, Ruhri C, Schmitt M, Graeff H, Höfler H. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives. Diagn Mol Pathol 1993;2:36-41.
39. Locker J. Tumor suppressor genes and the practice of surgical pathology. Hum Pathol 1995;26:359-61.
40. Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis RR. The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 1994;11:199-207.
41. Zafrani B, Leroyer A, Fourquet A, et al. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 1994;11:208-14.
42. Meyer JS. Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res Treat 1986;7:171-80.
43. Schnitt SJ. Pathology of in situ carcinoma. In: Harris JR, Hellman S, Henderson IC, Kinne DW, editors. Breast Diseases. 2nd edition. Philadelphia: J.B. Lippincott Co., 1991:229-44.